Stock XENE XENON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
36.56 USD -3.00% Intraday chart for Xenon Pharmaceuticals Inc. -1.19% -20.63%
Jun. 12 Transcript : Xenon Pharmaceuticals Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Jun. 04 Transcript : Xenon Pharmaceuticals Inc. - Shareholder/Analyst Call

Business Summary

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Number of employees: 255

Managers

Managers TitleAgeSince
Ian Mortimer CEO
 Chief Executive Officer 48 13-10-20
Sherry Aulin DFI
 Director of Finance/CFO 41 10-12-31
Christopher Kenney CTO
 Chief Tech/Sci/R&D Officer 53 21-08-22
Sheila M. Grant CTO
 Chief Tech/Sci/R&D Officer - 20-07-31
Jodi Regts IRO
 Public Communications Contact - 15-11-30
Christopher von Seggern PRN
 Corporate Officer/Principal 45 20-08-16
Andrea DiFabio LAW
 General Counsel 55 22-11-06
James Empfield PRN
 Corporate Officer/Principal - 16-01-31
Robin Sherrington PRN
 Corporate Officer/Principal 63 01-02-28
Shelley McCloskey HRO
 Human Resources Officer 64 19-09-16

Members of the board

Members of the board TitleAgeSince
Clarence Machado BRD
 Director/Board Member 60 20-11-04
Justin Gover BRD
 Director/Board Member 53 23-08-07
Gary Patou BRD
 Director/Board Member 65 03-12-31
Steven Gannon BRD
 Director/Board Member 62 15-05-20
Ian Mortimer CEO
 Chief Executive Officer 48 13-10-20
Dawn Svoronos BRD
 Director/Board Member 70 16-09-26
Elizabeth Garofalo BRD
 Director/Board Member 66 21-06-02
Gillian Cannon BRD
 Director/Board Member 60 23-08-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 75,468,883 74,291,475 ( 98.44 %) 0 98.44 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
8.748 %
6,601,830 8.748 % 251 M $
Avoro Capital Advisor LLC
7.509 %
5,666,666 7.509 % 216 M $
Driehaus Capital Management LLC
5.727 %
4,321,740 5.727 % 165 M $
Wellington Management Co. LLP
5.197 %
3,922,058 5.197 % 149 M $
Capital Research & Management Co. (World Investors)
3.553 %
2,681,537 3.553 % 102 M $
POLAR CAPITAL HOLDINGS PLC
3.461 %
2,612,108 3.461 % 99 M $
Paradigm BioCapital Advisors LP
3.293 %
2,484,874 3.293 % 95 M $
Capital Research & Management Co. (International Investors)
3.281 %
2,475,859 3.281 % 94 M $
Commodore Capital LP
2.872 %
2,167,793 2.872 % 83 M $
BlackRock Advisors LLC
2.243 %
1,693,018 2.243 % 64 M $

Company contact information

Xenon Pharmaceuticals, Inc.

3650 Gilmore Way Suite 200

V5G 4W8, Burnaby

+604 484 3300

http://www.xenon-pharma.com
address Xenon Pharmaceuticals Inc.(XENE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
36.56 USD
Average target price
58.79 USD
Spread / Average Target
+60.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XENON PHARMACEUTICALS INC. Stock Xenon Pharmaceuticals Inc.
-20.63% 2.76B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.44% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.94% 113B
ARGENX SE Stock argenx SE
+18.72% 26.22B
BIONTECH SE Stock BioNTech SE
-25.37% 19.01B
GENMAB A/S Stock Genmab A/S
-19.84% 15.71B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.20% 15.22B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.37% 14.72B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+59.91% 14.58B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.35% 13.84B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XENE Stock
  4. Company Xenon Pharmaceuticals Inc.